GVHD

View All

graft-versus-host-disease-gvhd-treatment
Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...

Find More

Pharma News and Update for Incyte and Aptose
AstraZeneca’s Farxiga; Incyte’s Jakavi; FDA Fast Track Status to HM43239 for R/R AML; Idorsia’s Insomnia Drug Quviviq; EU Approves Kymirah For Follicular Lymphoma; Perrigo Acquires HRA Pharma; Janssen Submits Marketing Authorisation Application to EMA

AstraZeneca’s Farxiga Meets Primary Endpoints in Phase 3 Heart Failure Trial Farxiga, an SGLT2 inhibitor from AstraZeneca, has shown positive results in a phase 3 Heart Failure trial, putting it back in contention with Jardiance from Boehringer Ingelheim and Eli Lilly. The DELIVER trial's top-line results demons...

Find More

Graft versus host disease
Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD

Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institu...

Find More

Pharma News
Fujifilm acquires global rights to Cynata’s novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop’s digital diabetes platform

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Find More

Japan's regenerative medicine
Japan is transforming its Healthcare sector through Regenerative Medicine

Regenerative medicine is an innovative approach to regrow and repair the damaged cells, tissues or organs. The process involves the regeneration of the lost body cells by stimulating the body’s own immune system. Regenerative medicine includes a group of biomedically engineered approaches that uses therapeutic stem...

Find More